Cleerly
Cleerly is a digital health company that provides FDA-cleared AI software for analyzing coronary CT angiography to quantify atherosclerosis, characterize plaque, and detect ischemia for hospitals, cardiology practices, and value-based care providers.
- Company typePrivate
- Founded2017
- HeadquartersDenver, United States
- Headcount101–250
- GTM typeB2B
- OfferingSoftware
What Cleerly does
Cleerly is a privately held digital health company founded in 2017 and headquartered in Denver, Colorado, that develops AI-driven software for non-invasive analysis of coronary artery disease (CAD). Its core platform, Cleerly Labs (FDA-cleared as a Software as a Medical Device), applies proprietary deep learning and machine learning algorithms — collectively branded AI-QCT or AI-CPA — to coronary CT angiography (CCTA) images to quantify and characterize atherosclerosis by measuring plaque volume, composition, length, and location, and to evaluate stenosis severity in 2D and 3D. The platform is built on more than two dozen algorithms trained on millions of images from over 40,000 patients and validated across nine multicenter clinical trials including CREDENCE, PACIFIC, CONFIRM2, and INVICTUS. Layered on this core are Cleerly ISCHEMIA (an FDA-cleared ischemia detection decision-support tool launched January 2024), Cleerly COMPARE (comparative analysis), Cleerly PREVIEW (debuting at ACC.26), and the workflow tool Cleerly Proxy.
Cleerly firmographics
Firmographics- Name
- Cleerly
- Legal name
- Cleerly, Inc.
- Website
- https://cleerlyhealth.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Cleerly is a digital health company that provides FDA-cleared AI software for analyzing coronary CT angiography to quantify atherosclerosis, characterize plaque, and detect ischemia for hospitals, cardiology practices, and value-based care providers.
- Ownership category
- akta.pro rank
Cleerly industry classification
Industry- Product category
- AI Cardiovascular Imaging Software
- NAICS
- Custom Computer Programming Services (541511)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- Teleradiology Platforms & Reading Workflow (HLACALAK)
Keywords
Where Cleerly is headquartered
LocationHeadquarters
- HQ city
- Denver
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Cleerly business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations
Revenue model
- Cleerly Labs Software Subscription / SaaS: Web-based software application licensed to healthcare providers, imaging centers, and healthcare referral partners under Master Services Agreements and Software & Services Terms; recurring enterprise SaaS model with Authorized User registration.
- Cleerly Professional / Analysis Services: Cleerly's proprietary service performs CCTA analysis on behalf of customers and provides access/analytical tooling to identify and assess anatomical and functional significance of coronary disease; complements software license with managed analysis offering.
- Reimbursement-based Plaque Analysis Utilization: Cleerly LABS Plaque Analysis is reimbursed under Medicare and major commercial payors (Aetna, Cigna, UnitedHealthcare, Humana, EviCore) with a Category I CPT code (75577) at a global reimbursement rate of $1,026 effective January 1, 2026, enabling per-study usage-based revenue tied to clinical adoption.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Enterprise SaaS (Cleerly Labs / Cleerly ISCHEMIA) priced via Master Services Agreement |
| Unit Pricing | Pay-as-you-go | CPT Category I Code (75577) Plaque Analysis — $1,026 global reimbursement |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels9 records
Cleerly product offering
Product offeringCore offering
Cleerly provides an FDA-cleared, web-based AI software platform (Cleerly Labs) that analyzes coronary CT angiography (CCTA) images to quantify and characterize coronary atherosclerosis by measuring plaque volume, composition, length, and location, while also evaluating stenosis severity and detecting likely ischemia. The platform is licensed under enterprise SaaS agreements to hospitals, health systems, imaging centers, and cardiology practices, with additional modules (Cleerly ISCHEMIA, Cleerly COMPARE, Cleerly Proxy) and a forthcoming enhancement (Cleerly PREVIEW). Complementary managed-analysis services perform CCTA evaluation on behalf of customers, reimbursed in part under Medicare and major commercial payors using Category I CPT code 75577.
Product overview
Cleerly offers a single, integrated AI-driven cardiovascular imaging platform delivered as web-based software, built on its proprietary AI-QCT (AI-Quantitative Coronary CT) / AI-CPA technology. The core product is Cleerly Labs (also branded Cleerly LABS / Cleerly Plaque Analysis), an FDA-cleared application that quantifies and assesses coronary artery disease (CAD) by measuring plaque volume, composition, length, location, and stenosis severity from Coronary Computed Tomography Angiography (CCTA) scans. Layered on top of Cleerly Labs are specialized modules and add-ons: Cleerly ISCHEMIA (an FDA-cleared decision support tool that estimates likely ischemia), Cleerly COMPARE (a comparative-analysis offering listed in the provider product menu), the workflow-optimization tool Cleerly Proxy, and the newly announced Cleerly PREVIEW enhancement debuting at ACC.26. The portfolio is delivered to healthcare providers (hospitals, health systems, imaging centers) and supported by reimbursement pathways including a new CPT Category I code (75577) effective January 1, 2026 at $1,026 global reimbursement.
Differentiator
Problem solved
Functional benefit
Brands
- Cleerly Labs: Web-based software application for trained medical professionals to view and analyze cardiac CT data, determining presence and extent of coronary plaques and stenosis in patients who underwent CCTA.
- Cleerly ISCHEMIA
- Cleerly COMPARE
- Cleerly PREVIEW
Products and services
- Cleerly Labs (Cleerly LABS Plaque Analysis) FDA-cleared, prescription-only web-based software application for trained medical professionals (cardiologists, radiologists, primary care physicians) to view and analyze cardiac CT data, measure and visualize coronary arteries, and determine the presence and extent of coronary plaque (atherosclerosis) and stenosis in patients who underwent CCTA for evaluation of coronary artery disease. Powered by AI-QCT / AI-CPA technology; reimbursed under Category I CPT code 75577 at $1,026 globally effective January 1, 2026.
- Cleerly ISCHEMIA FDA-cleared automated machine learning-based decision support tool indicated as a diagnostic aid for detecting likely ischemia associated with coronary artery disease in patients undergoing CT analysis using Cleerly Labs. Designed for healthcare providers evaluating patients with suspected CAD; complements clinician judgment rather than replacing it.
- Cleerly COMPARE Named offering within the Cleerly Labs suite listed in the For-HCPs product menu, intended for comparative CCTA analysis. Functionality details are not separately specified beyond its position in the product menu.
- Cleerly PREVIEW New Cleerly product enhancement introduced at ACC.26 as part of the AI-QCT imaging analysis offering for healthcare providers; specific capabilities beyond the debut announcement are not detailed in available sources.
- Cleerly Proxy Workflow solution that improves heart disease imaging workflows by enabling seamless data transmission between imaging sites and the Cleerly platform, supporting AI-based plaque analysis at hospitals and imaging centers.
Quantifiable outcome
- AUC improved from 0.62 to 0.75 (p<0.001) for MACE prediction with AI-QCT added to ESC RF-CL scores
- +7 more outcomes
Companies that use Cleerly
Customer profileNamed customers2 records
Segments5 records
Ideal customer profiles3 records
Cleerly technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability7 records
Feature7 records
Cleerly partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered flagship, major and core.
- MemorialCare Heart & Vascular InstituteflagshipMemorialCare systemwide implemented Cleerly's AI-powered coronary analysis technology across its hospitals in Southern California, starting with Long Beach Medical Center, to improve detection of coronary artery disease. MemorialCare is the first hospital in Los Angeles County to offer Cleerly AI-powered heart disease analysis quantifying total plaque volume and soft plaque.
- PowerScribe (Nuance/Microsoft)majorCleerly debuted PowerScribe integration at RSNA 2025 that maps and transfers CCTA report data to PowerScribe templates, reducing manual data entry and transcription errors and enabling efficient report generation and clinical documentation.
- Longevity HealthmajorLongevity Health launched Tennessee's first clinic dedicated to AI-powered heart and cancer imaging, becoming the first clinic in the area to offer Cleerly AI heart disease analyses.
- Cardiac Care AlliancecoreCleerly and Cardiac Care Alliance joined forces to revolutionize heart disease detection by optimizing appropriate procedures and transforming cardiac care with AI-powered imaging technology in value-based care settings.
- Bunkerhill HealthcoreCleerly (Denver) and Bunkerhill Health (San Francisco) announced a strategic partnership to expand access to FDA-cleared AI solutions for cardiac imaging. Under the agreement, Cleerly's hospital partners gain access to Bunkerhill's Careblocks technology for coronary artery calcium scoring, while Bunkerhill's hospital partners can use Cleerly's CCTA scan evaluations for patients with high CAC scores.
- Viz.aicoreViz.ai and Cleerly partnered to deliver critical insights to more cardiovascular care teams to identify and define atherosclerosis earlier through AI integration. The partnership connects Viz.ai's care coordination platform with Cleerly's AI-enabled CCTA analysis.
- TRANSFORM Trial PartnerscoreCleerly, alongside partners, announced the TRANSFORM Trial at AHA 2023 to evaluate personalized heart disease care strategies, generating evidence from the multicenter international cohort.
- American Heart Association Center for Health Technology & Innovation Innovators' NetworkmajorCleerly joined the American Heart Association Center for Health Technology & Innovation's Innovators' Network — a health care technology consortium that connects entrepreneurs, providers, researchers, and payers to develop innovative and scalable health tech solutions.
- CenegenicsmajorCleerly and Cenegenics partnered to offer heart disease prevention technology as part of Cenegenics' Performance Health Age Management Portfolio. Cenegenics' U.S. locations now offer Cleerly's AI-enabled approach to personalized heart care.
- Apex CardiologymajorL.A.-area Apex Cardiology partnered with Cleerly to offer a new standard of care for heart disease prevention, leveraging the AI-enabled approach to develop personalized heart care diagnoses and treatment plans.
- Heartbeat HealthcoreCleerly partnered with Heartbeat Health to increase access to early cardiac evaluations by combining Cleerly's AI-enabled approach to identifying early signs of heart disease with Heartbeat Health's nationwide footprint of cardiologists.
Scale indicators19 records
Recent moves8 records
Expansion highlights7 records
Cleerly competitors and assessment
Company assessmentDirect peers
- HeartFlow: HeartFlow is the most direct competitor to Cleerly, offering AI-driven CCTA analysis (FFRCT) for non-invasive assessment of coronary artery disease. Both companies target the same providers, payors, and clinical workflow and are currently engaged in active patent litigation.
- Elucid Bioimaging: Elucid Bioimaging develops AI-based software for cardiovascular plaque quantification and characterization from CCTA, directly competing with Cleerly's core AI-QCT product offering in plaque analysis.
- Circle Cardiovascular Imaging: Circle Cardiovascular Imaging provides post-processing software for cardiac CT and MR imaging, serving the same cardiology and radiology imaging centers that Cleerly targets with its AI-QCT platform.
Broad incumbents
- GE HealthCare: GE HealthCare is a global medical imaging incumbent with broad cardiac CT and AI-augmented imaging capabilities. Its distribution scale and OEM relationships position it as a potential integrated competitor or partner to standalone AI like Cleerly.
- Philips: Philips is a major healthcare technology incumbent with cardiac imaging systems, AI-enabled image analysis, and integrated cardiology informatics; it competes broadly with Cleerly across hospital cardiovascular imaging workflows.
- Siemens Healthineers: Siemens Healthineers is a major imaging OEM with cardiac CT, MR, and AI-augmented post-processing capabilities; its installed base in hospitals worldwide represents both a partnership channel and competitive threat to Cleerly.
- Tempus AI: Tempus AI is a public precision medicine company applying AI to clinical and molecular data; while broader than imaging, it competes with Cleerly for AI-driven healthcare budgets and increasingly overlaps in cardiovascular data analytics.
Emerging players
- Aidoc: Aidoc provides AI-driven image analysis across multiple radiology modalities (CT, MR) with deep hospital EHR integration. While broader than Cleerly's cardiovascular focus, Aidoc competes for hospital AI imaging budgets and workflow integration.
- Viz.ai: Viz.ai is an AI-driven care coordination platform originally focused on stroke and now expanding into cardiovascular. As a strategic partner of Cleerly, Viz.ai represents both a complementary distribution channel and an emerging cardiovascular AI competitor.
- HeartVista: HeartVista offers AI-assisted cardiac MRI acquisition and analysis; while focused on MR rather than CT, it competes for the same cardiology AI imaging budgets and clinical workflow integration at hospitals.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Cleerly social profiles
Digital presenceCleerly compliance and trust
Trust signalCompliance4 records
Cleerly financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cleerly leadership team
Management profileNumber of profiles
Profiles10 records
Cleerly funding detail
Funding detailFunding overview
Funding rounds4 records
Investors19 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cleerly M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cleerly
What does Cleerly do?
Cleerly provides an FDA-cleared, web-based AI software platform (Cleerly Labs) that analyzes coronary CT angiography (CCTA) images to quantify and characterize coronary atherosclerosis by measuring plaque volume, composition, length, and location, while also evaluating stenosis severity and detecting likely ischemia. The platform is licensed under enterprise SaaS agreements to hospitals, health systems, imaging centers, and cardiology practices, with additional modules (Cleerly ISCHEMIA, Cleerly COMPARE, Cleerly Proxy) and a forthcoming enhancement (Cleerly PREVIEW). Complementary managed-analysis services perform CCTA evaluation on behalf of customers, reimbursed in part under Medicare and major commercial payors using Category I CPT code 75577.
Is Cleerly a public or private company?
Cleerly is a private company. It is classified as venture growth investor backed and is currently operating.
When was Cleerly founded?
Cleerly was founded in 2017. It employs 101 to 250 people.
Where is Cleerly based?
Cleerly is headquartered in Denver, United States, in the North America region.
How does Cleerly make money?
Three revenue lines are on record. Cleerly Labs Software Subscription / SaaS are the primary driver. The others are cleerly Professional / Analysis Services and reimbursement-based Plaque Analysis Utilization.
Who are Cleerly's main competitors?
Direct peers on record are HeartFlow, Elucid Bioimaging and Circle Cardiovascular Imaging. Broad incumbents are GE HealthCare, Philips, Siemens Healthineers and Tempus AI. Emerging players are Aidoc, Viz.ai and HeartVista.
Does Cleerly have an API?
No public API is recorded for Cleerly.
What industry is Cleerly in?
Cleerly's product category is AI Cardiovascular Imaging Software. Its primary akta.pro industry code is HLACALAK, Teleradiology Platforms & Reading Workflow. Its NAICS code is 541511 and its SIC code is 7372.